Li Yixuan, Luo Liuxiong, Senicar Lenart, Asrosa Rica, Kizilates Burcu, Xing Kaizhong, Torres Elias, Xu Lizhou, Li Danyang, Graham Neil, Heslegrave Amanda, Zetterberg Henrik, Sharp David J, Li Bing
Institute for Materials Discovery, Department of Chemistry, University College London, London, WC1E 7JE, UK.
School of Materials Science and Engineering, Central South University, Changsha, 410083, P. R. China.
Adv Healthc Mater. 2024 Dec;13(30):e2401966. doi: 10.1002/adhm.202401966. Epub 2024 Sep 2.
Accurate assessment of neurological disease through monitoring of biomarkers has been made possible using the antibody-based assays. But these assays suffer from expensive development of antibody probes, reliance on complicated equipments, and high maintenance costs. Here, using the novel reduced graphene oxide/polydopamine-molecularly imprinted polymer (rGO/PDA-MIP) as the probe layer, a robust electrochemical sensing platform is demonstrated for the ultrasensitive detection of glial fibrillary acidic protein (GFAP), a biomarker for a range of neurological diseases. A miniaturized integrated circuit readout system is developed to interface with the electrochemical sensor, which empowers it with the potential to be used as a point-of-care (POC) diagnostic tool in primary clinical settings. This innovative platform demonstrated good sensitivity, selectivity, and stability, with imprinting factor evaluated as 2.8. A record low limit-of-detection (LoD) is down to 754.5 ag mL, with a wide dynamic range from 1 to 10 fg mL. The sensing platform is validated through the analysis of GFAP in clinical plasma samples, yielding a recovery rate range of 81.6-108.8% compared to Single Molecule Array (Simoa). This cost-effective and user-friendly sensing platform holds the potential to be deployed in primary and resource-limited clinical settings for the assessment of neurological diseases.
通过基于抗体的检测方法，借助生物标志物监测来准确评估神经疾病已成为可能。但这些检测方法存在抗体探针开发成本高昂、依赖复杂设备以及维护成本高等问题。在此，以新型还原氧化石墨烯/聚多巴胺分子印迹聚合物（rGO/PDA-MIP）作为探针层，展示了一种用于超灵敏检测胶质纤维酸性蛋白（GFAP）的强大电化学传感平台，GFAP是一系列神经疾病的生物标志物。开发了一种小型化集成电路读出系统与电化学传感器对接，使其有潜力在基层临床环境中用作即时检测（POC）诊断工具。这个创新平台展现出良好的灵敏度、选择性和稳定性，印迹因子评估为2.8。创纪录的低检测限（LoD）低至754.5 ag/mL，动态范围宽达1至10 fg/mL。通过分析临床血浆样本中的GFAP对传感平台进行验证，与单分子阵列（Simoa）相比，回收率范围为81.6 - 108.8%。这个经济高效且用户友好的传感平台有潜力部署在基层和资源有限的临床环境中用于神经疾病评估。
